Announcements Trials
Browse Landscape

Phase

Phase 2/3 2Phase 3 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

NIH 3OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3

Conditions

Squamous Cell Carcinoma of Head and Neck 5Mouth Neoplasms 3Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Carcinoma 3Oropharyngeal Neoplasms 2Rectal Neoplasms 1Nasopharyngeal Carcinoma 1Lymphoid Interstitial Pneumonia 1Locally Recurrent Skin Squamous Cell Carcinoma 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Specimen Handling 9Magnetic Resonance Spectroscopy 9Cisplatin 6Biopsy 5Paclitaxel 4pembrolizumab 3Platinum 3Immunoglobulin G 3Disulfides 3Cetuximab 3Carboplatin 31,2-diaminocyclohexaneplatinum II citrate 3(225)Ac-DOTA-c(RGDyK) 3ipatasertib 2cemiplimab 2Taxes 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Radiosurgery 2Radiation 2Docetaxel 2Cytoreduction Surgical Procedures 2Bevacizumab 2ALT-803 2peposertib 1peginterferon alfa-2b 1interferon gamma-1b 1fludarabine phosphate 1fludarabine 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × Carcinoma × (225)Ac-DOTA-c(RGDyK) × Clear all
NCT05063552 2026-06-03

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
430 enrolled
Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06589804 2026-06-03

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

National Cancer Institute (NCI)

Phase 3 Recruiting
158 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms

NCT03258554 2026-06-02

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

National Cancer Institute (NCI)

Phase 2/3 Completed
196 enrolled 31 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡